细胞减灭术加腹腔热灌注化疗治疗胃癌腹膜癌的系统分析

发布时间：2018-11-23 09:51

【摘要】：目的系统分析肿瘤细胞减灭术(cytoreductive surgery,CRS)加腹腔热灌注化疗(hyperthermic intraperitoneal chemotherapy,HIPEC)治疗胃癌腹膜癌(gastric cancer peritoneal carcinomatosis,GC PC)的应用现状及发展方向。方法检索CRS+HIPEC治疗GC PC相关临床研究文献,提取生存及安全性相关数据,进行系统分析。结果 GC PC的自然病程不超过5月,CRS+HIPEC可延长GC PC患者总生存期(overall survival,OS)。在前瞻性临床研究中CRS+HIPEC组中位OS为11.0月,在回顾性临床研究中CRS+HIPEC组中位OS为13.3月。CRS+HIPEC治疗GC PC围手术期死亡率低于6.5%,严重不良事件发生率无显著上升。结论 CRS+HIPEC治疗GC PC疗效显著,有望成为部分经选择的GC PC患者的首选治疗。
[Abstract]:Objective to analyze the application and development of tumor cell reduction (cytoreductive surgery,CRS) combined with intraperitoneal hyperthermic infusion chemotherapy (hyperthermic intraperitoneal chemotherapy,HIPEC) in the treatment of gastric cancer with peritoneal carcinoma (gastric cancer peritoneal carcinomatosis,GC PC). Methods to retrieve the clinical literatures related to CRS HIPEC therapy for GC PC and to extract the survival and safety data for systematic analysis. Results the natural course of GC PC did not exceed 5 months, CRS HIPEC could prolong the total survival time (overall survival,OS) of GC PC patients. In prospective clinical study, the median OS of CRS HIPEC group was 11.0 months. In retrospective clinical study, the median OS of CRS HIPEC group was 13.3 months and the perioperative mortality of GC PC was lower than 6.5 months. The incidence of severe adverse events did not increase significantly. Conclusion CRS HIPEC is effective in the treatment of GC PC, and it is expected to be the first choice for selected GC PC patients.
【作者单位】：首都医科大学附属北京世纪坛医院腹膜肿瘤外科;天津医科大学肿瘤医院胃部肿瘤科国家肿瘤临床医学研究中心天津市肿瘤防治重点实验室;北京大学肿瘤医院暨北京市肿瘤防治研究所胃肠肿瘤中心恶性肿瘤发病机制及转化研究教育部重点实验室;
【基金】：首都临床特色应用研究与成果推广项目(Z161100000516077) 北京市自然科学基金(7172108) 首都医科大学附属北京世纪坛医院重点学科建设项目(2016fmzlwk)
【分类号】：R735

【相似文献】